Earnings call transcript: Cegedim’s Q1 2026 reveals mixed results

Cegedim reported Q1 2026 revenue of 159.6 million euros, down 1% year over year, with the Cloud and Support segment falling 25% due to the end of a major outsourcing contract. Offsetting that weakness, Business Services rose 3.1% to 48.0 million euros and Health and Provident Insurance edged up to 41.6 million euros. Management reaffirmed full-year 2026 guidance for like-for-like growth above 2% and higher adjusted operating income, and the stock was unchanged at 12.15 euros.

Analysis

The key read-through is not the headline decline, but the quality of the offset: management is showing that lower-margin, contract-driven revenue is being replaced by higher-retention, regulatory- or workflow-anchored activity. That matters because it reduces revenue volatility into 2026 and likely improves mix, so the market should treat this as a transition quarter rather than a demand miss. The fact that guidance was reiterated despite the loss of a meaningful outsourcing contract suggests the underlying book is still healthy enough to absorb a known air pocket.

The bigger second-order catalyst is the French e-invoicing rollout. The near-term setup is noisy because clients are late and implementation revenue is project-based, but the regime change typically creates a second wave: first integration spend, then recurring transaction flow. That means revenue inflection is likely to lag the legal deadline by 2-4 quarters, with the strongest operating leverage showing up in 2027 rather than immediately after September 2026.

Consensus risk is likely underestimating mix improvement versus absolute growth disappointment. The market will anchor on the cloud/support decline and miss that business services and cross-border healthcare software are doing the work of re-rating the margin structure. If those growth areas sustain mid-single-digit momentum while the drag rolls off, earnings can inflect faster than sales, which is the path to multiple expansion in a low-growth software name.

The main bear case is execution: late client adoption in e-invoicing can push the monetization curve rightward, and legacy healthcare churn can keep the top line looking flattish into multiple prints. But because the company is already flagging 2027 double-digit upside in one segment, the setup is for a sequence of better forward revisions rather than a one-quarter surprise.

Key Decisions for Investors

• Go long ALCGM on pullbacks, with a 6-12 month horizon: thesis is mix/operating leverage rather than headline revenue growth; upside case is rerating if 2026 exits with improving sequential growth and margin expansion.
• Pair trade: long ALCGM / short a lower-quality European small-cap software name with more contract concentration, to isolate the reversion from one-off drag to recurring workflow revenue over the next 2-3 quarters.
• Buy a small starter position ahead of the September 2026 e-invoicing deadline, then add on confirmation that implementation revenue is converting into recurring flow in Q4 2026/Q1 2027; risk is delayed customer adoption.
• If available, use call spreads rather than stock for the 12-month view: the setup favors gradual positive revisions, so defined-risk upside exposure is preferable to outright beta.
• Avoid chasing on the first post-deadline pop; the better entry is after the market realizes the revenue bridge is 2-4 quarters longer than the regulatory headline.